A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
This study is testing a new experimental pill called S241656 to see if it can safely help treat various advanced solid tumors. It is designed for patients whose cancers have specific gene mutations (like KRAS or BRAF) that help the cancer grow.
This trial is for adults with advanced or recurring solid tumors, such as lung, colon, or pancreatic cancer, that have certain gene changes. You must have generally stable health, including good kidney and liver function, and have recovered from past cancer treatments.
Participants will take the study drug orally in 28-day cycles, either alone or alongside other standard cancer therapies. You will be closely monitored by the medical team to see how well you handle the treatment and how the cancer responds over time.
The study is currently recruiting patients at medical centers in Arizona and California. You can discuss with your doctor whether these locations are a good fit for your situation.
- 1The study tests a new medication for cancers with specific 'driver' mutations.
- 2The drug is taken as a pill at home, which may offer more convenience than intravenous treatments.
- 3Researchers are carefully checking for safety while looking for the best dose to fight the cancer.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.